Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning

 
• By Brenda Sandburg

The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.

Eye drop compounding
The US FDA objects to promotions for a compounded eye drop product. • Source: Shutterstock

More from Compliance

More from Pink Sheet